Skip to content

Multi-center study on intelligent early warning system of severe pneumonia caused by influenza A-bacteria co-infection driven by GZMB

Multi-center study on intelligent early warning system of severe pneumonia caused by influenza A-bacteria co-infection driven by GZMB

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119150
Enrollment
Unknown
Registered
2026-02-24
Start date
2026-02-24
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-acquired pneumonia

Interventions

Influenza A-bacterial co-infection:None

Sponsors

Fuzhou University Affiliated Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Meet the primary screening criteria: (1) Adult patients over 18 years old; (2) The clinical diagnosis was community-acquired pneumonia, which met the diagnostic criteria of ATS/IDSA; (3) Influenza A virus was confirmed positive by RT-PCR; (4) Admission within 7 days of onset; (5) Sign the informed consent form; (6) Expected hospitalization time >= 48 hours. 2. Diagnostic criteria of bacterial infection (meet any of the following conditions): (1) positive blood culture (2) positive sputum culture (qualified sputum specimen) (3) positive bronchoalveolar lavage fluid culture (4) positive bacterial PCR detection (5) procalcitonin >= 0.25ng/mL and effective antibacterial treatment. 3. Have complete dynamic monitoring data within 48 hours.

Exclusion criteria

Exclusion criteria: 1.patients with immunodeficiency diseases (HIV infection, primary immunodeficiency disease, etc.); 2. Malignant tumor patients (within 3 years); 3. Long-term use of immunosuppressants (> 3 months); 4. Severe hepatic and renal insufficiency (Child-pugh grade C or serum creatinine > 300µ mol/L); 5. Pregnant or lactating women; 6. Patients whose expected survival time is less than 3 months; 7. Patients who cannot obtain informed consent or have poor compliance; 8. Previous participation in other clinical trials that may affect the results of this study, or other uncertain factors.

Design outcomes

Primary

MeasureTime frame
GZMB;

Secondary

MeasureTime frame
Inflammation markers (CRP, PCT, IL-6, TNF-a, IL-1ß, etc.);Immune markers (GNLY, IL-7, etc.);

Countries

China

Contacts

Public ContactLong Huang

Fuzhou University Affiliated Provincial Hospital

18060473649@189.cn+86 591 8861 8701

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026